Effect of trimetazidine and verapamil on the cardiomyopathic hamster myosin phenotype
In this study we investigated whether long‐term trimetazidine (anti‐ischaemic drug) therapy alters the ventricular myosin heavy chain (MHC) isoform composition in a model of cardiomyopathy. MHC isoforms were analysed in the native state by electrophoresis in a pyrophosphate buffer. Myosin isoform pa...
Gespeichert in:
| Veröffentlicht in: | British journal of pharmacology 1998-02, Vol.123 (4), p.611-616 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 616 |
|---|---|
| container_issue | 4 |
| container_start_page | 611 |
| container_title | British journal of pharmacology |
| container_volume | 123 |
| creator | D'hahan, Nathalie Taouil, Karima Janmot, Chantal Morel, Jean‐Emile |
| description | In this study we investigated whether long‐term trimetazidine (anti‐ischaemic drug) therapy alters the ventricular myosin heavy chain (MHC) isoform composition in a model of cardiomyopathy.
MHC isoforms were analysed in the native state by electrophoresis in a pyrophosphate buffer. Myosin isoform patterns were studied in cardiac muscle from cardiomyopathic hamsters (CMH) of the BIO 14 : 6 strain during the time course of the disease and compared with those of healthy golden hamsters (F1B). The correlation between myosin profile and Ca2+‐activated ATPase activity was determined from 220 days.
At the stage of insufficiency (350 days), CMH presented the most abnormal phenotype with 53% V1‐24% V3 compared to 79% V1‐7% V3 (P |
| doi_str_mv | 10.1038/sj.bjp.0701643 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1565203</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>16207080</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4890-b9a49ba879fa8e2263c7cc1d90fd5d7c6f69e7c032cacde5ab220421bdce77a03</originalsourceid><addsrcrecordid>eNqFkUFv1DAQhS0EKkvhyg3JB8Qtix3HsXNBgqq0SJXgQM_WxJkQrxI72Nmi5dfj1UarcurJ0rxvnmfmEfKWsy1nQn9Mu227m7dMMV5X4hnZ8ErVhRSaPycbxpgqONf6JXmV0o6xLCp5QS4ayZVQekPur_se7UJDT5foJlzgr-ucRwq-ow8YYYbJjTR4ugxILcTOhekQZlgGZ-kAU1ow0lxJztN5QB-Ww4yvyYsexoRv1veS3H-9_nl1W9x9v_l29fmusJVuWNE2UDUtaNX0oLEsa2GVtbxrWN_JTtm6rxtUlonSgu1QQluWrCp521lUCpi4JJ9OvvO-nTBX_RJhNHPeBOLBBHDmf8W7wfwKD4bLWpZMZIMPq0EMv_eYFjO5ZHEcwWPYJ6MaVQlWPw3yuswR6ONI2xNoY0gpYn-ehjNzTMykncmJmTWx3PDu8Q5nfI0o6-9XHZKFsY_grUtnrORKM8kzJk7YHzfi4YlPzZcft_J4gH_gxLKB</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16207080</pqid></control><display><type>article</type><title>Effect of trimetazidine and verapamil on the cardiomyopathic hamster myosin phenotype</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wiley Free Content</source><source>Wiley Online Library All Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>D'hahan, Nathalie ; Taouil, Karima ; Janmot, Chantal ; Morel, Jean‐Emile</creator><creatorcontrib>D'hahan, Nathalie ; Taouil, Karima ; Janmot, Chantal ; Morel, Jean‐Emile</creatorcontrib><description>In this study we investigated whether long‐term trimetazidine (anti‐ischaemic drug) therapy alters the ventricular myosin heavy chain (MHC) isoform composition in a model of cardiomyopathy.
MHC isoforms were analysed in the native state by electrophoresis in a pyrophosphate buffer. Myosin isoform patterns were studied in cardiac muscle from cardiomyopathic hamsters (CMH) of the BIO 14 : 6 strain during the time course of the disease and compared with those of healthy golden hamsters (F1B). The correlation between myosin profile and Ca2+‐activated ATPase activity was determined from 220 days.
At the stage of insufficiency (350 days), CMH presented the most abnormal phenotype with 53% V1‐24% V3 compared to 79% V1‐7% V3 (P<0.001), in F1B. Trimetazidine was administered to cardiomyopathic hamsters from the early stage of active disease (30 days) to the congestive stages (220–350 days). Within 65 days, trimetazidine treatment, in CMH and F1B, reduced V1 to a low level (53% and 62%, respectively), which remained constant throughout the treatment. This level was similar to that in 220 and 350 days‐old untreated‐CMH. In sharp contrast, a standard calcium blocker, verapamil, administered to CMH in the same conditions resulted in a higher V1 (about 70%) and higher global myosin ATPase activity from 220 days.
Previous results in terms of hypertrophy and survival, compared to these results, suggest that verapamil and trimetazidine treatments reveal a disssociation between ventricular hypertrophy and isomyosin distribution. In addition, the shift in favour of V3 may not necessarily be an aggravating factor of the disease but an adaptative compensatory event.
British Journal of Pharmacology (1998) 123, 611–616; doi:10.1038/sj.bjp.0701643</description><identifier>ISSN: 0007-1188</identifier><identifier>EISSN: 1476-5381</identifier><identifier>DOI: 10.1038/sj.bjp.0701643</identifier><identifier>PMID: 9517378</identifier><identifier>CODEN: BJPCBM</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Animals ; Antianginal agents. Coronary vasodilator agents ; Biological and medical sciences ; Calcium Channel Blockers - therapeutic use ; Calcium-Transporting ATPases - metabolism ; cardiac muscle ; Cardiomyopathies - drug therapy ; Cardiomyopathies - enzymology ; Cardiomyopathies - genetics ; Cardiomyopathy ; Cardiovascular system ; Cricetinae ; Electrophoresis, Polyacrylamide Gel ; hypertrophy ; ischaemia ; Medical sciences ; Mesocricetus ; myosin ATPase activity ; myosin isozymes ; Myosins - genetics ; Myosins - isolation & purification ; Pharmacology. Drug treatments ; Phenotype ; survival ; trimetazidine ; Trimetazidine - therapeutic use ; Vasodilator Agents - therapeutic use ; verapamil ; Verapamil - therapeutic use</subject><ispartof>British journal of pharmacology, 1998-02, Vol.123 (4), p.611-616</ispartof><rights>1998 British Pharmacological Society</rights><rights>1998 INIST-CNRS</rights><rights>Copyright 1998, Nature Publishing Group 1998 Nature Publishing Group</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4890-b9a49ba879fa8e2263c7cc1d90fd5d7c6f69e7c032cacde5ab220421bdce77a03</citedby><cites>FETCH-LOGICAL-c4890-b9a49ba879fa8e2263c7cc1d90fd5d7c6f69e7c032cacde5ab220421bdce77a03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1565203/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1565203/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,1417,1433,27924,27925,45574,45575,46409,46833,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2178051$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9517378$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>D'hahan, Nathalie</creatorcontrib><creatorcontrib>Taouil, Karima</creatorcontrib><creatorcontrib>Janmot, Chantal</creatorcontrib><creatorcontrib>Morel, Jean‐Emile</creatorcontrib><title>Effect of trimetazidine and verapamil on the cardiomyopathic hamster myosin phenotype</title><title>British journal of pharmacology</title><addtitle>Br J Pharmacol</addtitle><description>In this study we investigated whether long‐term trimetazidine (anti‐ischaemic drug) therapy alters the ventricular myosin heavy chain (MHC) isoform composition in a model of cardiomyopathy.
MHC isoforms were analysed in the native state by electrophoresis in a pyrophosphate buffer. Myosin isoform patterns were studied in cardiac muscle from cardiomyopathic hamsters (CMH) of the BIO 14 : 6 strain during the time course of the disease and compared with those of healthy golden hamsters (F1B). The correlation between myosin profile and Ca2+‐activated ATPase activity was determined from 220 days.
At the stage of insufficiency (350 days), CMH presented the most abnormal phenotype with 53% V1‐24% V3 compared to 79% V1‐7% V3 (P<0.001), in F1B. Trimetazidine was administered to cardiomyopathic hamsters from the early stage of active disease (30 days) to the congestive stages (220–350 days). Within 65 days, trimetazidine treatment, in CMH and F1B, reduced V1 to a low level (53% and 62%, respectively), which remained constant throughout the treatment. This level was similar to that in 220 and 350 days‐old untreated‐CMH. In sharp contrast, a standard calcium blocker, verapamil, administered to CMH in the same conditions resulted in a higher V1 (about 70%) and higher global myosin ATPase activity from 220 days.
Previous results in terms of hypertrophy and survival, compared to these results, suggest that verapamil and trimetazidine treatments reveal a disssociation between ventricular hypertrophy and isomyosin distribution. In addition, the shift in favour of V3 may not necessarily be an aggravating factor of the disease but an adaptative compensatory event.
British Journal of Pharmacology (1998) 123, 611–616; doi:10.1038/sj.bjp.0701643</description><subject>Animals</subject><subject>Antianginal agents. Coronary vasodilator agents</subject><subject>Biological and medical sciences</subject><subject>Calcium Channel Blockers - therapeutic use</subject><subject>Calcium-Transporting ATPases - metabolism</subject><subject>cardiac muscle</subject><subject>Cardiomyopathies - drug therapy</subject><subject>Cardiomyopathies - enzymology</subject><subject>Cardiomyopathies - genetics</subject><subject>Cardiomyopathy</subject><subject>Cardiovascular system</subject><subject>Cricetinae</subject><subject>Electrophoresis, Polyacrylamide Gel</subject><subject>hypertrophy</subject><subject>ischaemia</subject><subject>Medical sciences</subject><subject>Mesocricetus</subject><subject>myosin ATPase activity</subject><subject>myosin isozymes</subject><subject>Myosins - genetics</subject><subject>Myosins - isolation & purification</subject><subject>Pharmacology. Drug treatments</subject><subject>Phenotype</subject><subject>survival</subject><subject>trimetazidine</subject><subject>Trimetazidine - therapeutic use</subject><subject>Vasodilator Agents - therapeutic use</subject><subject>verapamil</subject><subject>Verapamil - therapeutic use</subject><issn>0007-1188</issn><issn>1476-5381</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUFv1DAQhS0EKkvhyg3JB8Qtix3HsXNBgqq0SJXgQM_WxJkQrxI72Nmi5dfj1UarcurJ0rxvnmfmEfKWsy1nQn9Mu227m7dMMV5X4hnZ8ErVhRSaPycbxpgqONf6JXmV0o6xLCp5QS4ayZVQekPur_se7UJDT5foJlzgr-ucRwq-ow8YYYbJjTR4ugxILcTOhekQZlgGZ-kAU1ow0lxJztN5QB-Ww4yvyYsexoRv1veS3H-9_nl1W9x9v_l29fmusJVuWNE2UDUtaNX0oLEsa2GVtbxrWN_JTtm6rxtUlonSgu1QQluWrCp521lUCpi4JJ9OvvO-nTBX_RJhNHPeBOLBBHDmf8W7wfwKD4bLWpZMZIMPq0EMv_eYFjO5ZHEcwWPYJ6MaVQlWPw3yuswR6ONI2xNoY0gpYn-ehjNzTMykncmJmTWx3PDu8Q5nfI0o6-9XHZKFsY_grUtnrORKM8kzJk7YHzfi4YlPzZcft_J4gH_gxLKB</recordid><startdate>199802</startdate><enddate>199802</enddate><creator>D'hahan, Nathalie</creator><creator>Taouil, Karima</creator><creator>Janmot, Chantal</creator><creator>Morel, Jean‐Emile</creator><general>Blackwell Publishing Ltd</general><general>Nature Publishing</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>199802</creationdate><title>Effect of trimetazidine and verapamil on the cardiomyopathic hamster myosin phenotype</title><author>D'hahan, Nathalie ; Taouil, Karima ; Janmot, Chantal ; Morel, Jean‐Emile</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4890-b9a49ba879fa8e2263c7cc1d90fd5d7c6f69e7c032cacde5ab220421bdce77a03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Animals</topic><topic>Antianginal agents. Coronary vasodilator agents</topic><topic>Biological and medical sciences</topic><topic>Calcium Channel Blockers - therapeutic use</topic><topic>Calcium-Transporting ATPases - metabolism</topic><topic>cardiac muscle</topic><topic>Cardiomyopathies - drug therapy</topic><topic>Cardiomyopathies - enzymology</topic><topic>Cardiomyopathies - genetics</topic><topic>Cardiomyopathy</topic><topic>Cardiovascular system</topic><topic>Cricetinae</topic><topic>Electrophoresis, Polyacrylamide Gel</topic><topic>hypertrophy</topic><topic>ischaemia</topic><topic>Medical sciences</topic><topic>Mesocricetus</topic><topic>myosin ATPase activity</topic><topic>myosin isozymes</topic><topic>Myosins - genetics</topic><topic>Myosins - isolation & purification</topic><topic>Pharmacology. Drug treatments</topic><topic>Phenotype</topic><topic>survival</topic><topic>trimetazidine</topic><topic>Trimetazidine - therapeutic use</topic><topic>Vasodilator Agents - therapeutic use</topic><topic>verapamil</topic><topic>Verapamil - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>D'hahan, Nathalie</creatorcontrib><creatorcontrib>Taouil, Karima</creatorcontrib><creatorcontrib>Janmot, Chantal</creatorcontrib><creatorcontrib>Morel, Jean‐Emile</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>D'hahan, Nathalie</au><au>Taouil, Karima</au><au>Janmot, Chantal</au><au>Morel, Jean‐Emile</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of trimetazidine and verapamil on the cardiomyopathic hamster myosin phenotype</atitle><jtitle>British journal of pharmacology</jtitle><addtitle>Br J Pharmacol</addtitle><date>1998-02</date><risdate>1998</risdate><volume>123</volume><issue>4</issue><spage>611</spage><epage>616</epage><pages>611-616</pages><issn>0007-1188</issn><eissn>1476-5381</eissn><coden>BJPCBM</coden><abstract>In this study we investigated whether long‐term trimetazidine (anti‐ischaemic drug) therapy alters the ventricular myosin heavy chain (MHC) isoform composition in a model of cardiomyopathy.
MHC isoforms were analysed in the native state by electrophoresis in a pyrophosphate buffer. Myosin isoform patterns were studied in cardiac muscle from cardiomyopathic hamsters (CMH) of the BIO 14 : 6 strain during the time course of the disease and compared with those of healthy golden hamsters (F1B). The correlation between myosin profile and Ca2+‐activated ATPase activity was determined from 220 days.
At the stage of insufficiency (350 days), CMH presented the most abnormal phenotype with 53% V1‐24% V3 compared to 79% V1‐7% V3 (P<0.001), in F1B. Trimetazidine was administered to cardiomyopathic hamsters from the early stage of active disease (30 days) to the congestive stages (220–350 days). Within 65 days, trimetazidine treatment, in CMH and F1B, reduced V1 to a low level (53% and 62%, respectively), which remained constant throughout the treatment. This level was similar to that in 220 and 350 days‐old untreated‐CMH. In sharp contrast, a standard calcium blocker, verapamil, administered to CMH in the same conditions resulted in a higher V1 (about 70%) and higher global myosin ATPase activity from 220 days.
Previous results in terms of hypertrophy and survival, compared to these results, suggest that verapamil and trimetazidine treatments reveal a disssociation between ventricular hypertrophy and isomyosin distribution. In addition, the shift in favour of V3 may not necessarily be an aggravating factor of the disease but an adaptative compensatory event.
British Journal of Pharmacology (1998) 123, 611–616; doi:10.1038/sj.bjp.0701643</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>9517378</pmid><doi>10.1038/sj.bjp.0701643</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1188 |
| ispartof | British journal of pharmacology, 1998-02, Vol.123 (4), p.611-616 |
| issn | 0007-1188 1476-5381 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1565203 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wiley Free Content; Wiley Online Library All Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Animals Antianginal agents. Coronary vasodilator agents Biological and medical sciences Calcium Channel Blockers - therapeutic use Calcium-Transporting ATPases - metabolism cardiac muscle Cardiomyopathies - drug therapy Cardiomyopathies - enzymology Cardiomyopathies - genetics Cardiomyopathy Cardiovascular system Cricetinae Electrophoresis, Polyacrylamide Gel hypertrophy ischaemia Medical sciences Mesocricetus myosin ATPase activity myosin isozymes Myosins - genetics Myosins - isolation & purification Pharmacology. Drug treatments Phenotype survival trimetazidine Trimetazidine - therapeutic use Vasodilator Agents - therapeutic use verapamil Verapamil - therapeutic use |
| title | Effect of trimetazidine and verapamil on the cardiomyopathic hamster myosin phenotype |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T18%3A46%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20trimetazidine%20and%20verapamil%20on%20the%20cardiomyopathic%20hamster%20myosin%20phenotype&rft.jtitle=British%20journal%20of%20pharmacology&rft.au=D'hahan,%20Nathalie&rft.date=1998-02&rft.volume=123&rft.issue=4&rft.spage=611&rft.epage=616&rft.pages=611-616&rft.issn=0007-1188&rft.eissn=1476-5381&rft.coden=BJPCBM&rft_id=info:doi/10.1038/sj.bjp.0701643&rft_dat=%3Cproquest_pubme%3E16207080%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16207080&rft_id=info:pmid/9517378&rfr_iscdi=true |